All Perspectives

International Trade & Investment Partner James Kim will lead a discussion at DesignCon 2026 on February 25th.

FDA Practice Leader and Agriculture & AgTech Industry Leader Karen Carr will present to the Plant Agriculture & Pesticide Regulations policy committee at the 2026 National Association of State Departments of Agriculture (NASDA) Winter Policy Conference on February 3, 2026.

International Trade & Investment Partner and Customs & Import Compliance Practice Leader Angela Santos will present on recent developments in international trade at ABA International Law Section’s The Americas Conference on January 27, 2026.

Partner J. Michael Showalter was quoted on how the Environmental Protection Agency’s (EPA) new “compliance first” doctrine may not mean less agency enforcement, despite concerns from environmental advocates.

AFS Partners Todd Angkatavanich and Lauren Wolven will present at the 2026 Heckerling Institute on January 13-14, 2026 in Orlando, Florida.

The 2026 District of Columbia elections may be the most consequential elections since the advent of home rule in 1975. Against a backdrop of greater federal intervention into the city’s affairs, depleting federal resources, and local budget pressures, many of the city’s most important local offices will have new leadership after the elections in November.

Last month, the US Food and Drug Administration (FDA) issued a draft guidance explaining how it intends to implement the mandatory recall authority established under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

A receivership is a court-supervised tool to stabilize operations of a distressed borrower, ring-fence pledged revenues, and drive recoveries for municipal bondholders when bankruptcy is not available or not desirable.

Last month, a federal court in Maine halted the US Department of Health and Human Services (HHS) Health Resources and Services Administration’s (HRSA) 340B Rebate Model Pilot Program in its tracks — a mere four days before it was to go into effect.

As we approach the end of the first year of the second Trump Administration, many in the health care sector continue to closely watch federal enforcement trends to identify government priorities going forward.

Over the past year, both the executive branch and the courts sought to pare back certain stringent aspects of National Environmental Policy Act (NEPA) reviews. However, a decision issued in December 2025 illustrates that agencies cannot defer conducting NEPA-required reviews until after project approval.

On December 22, 2025, the US Department of Justice (DOJ) sued Stanley Black & Decker in the US District Court for the District of Maryland, alleging violations of the Consumer Product Safety Act (CPSA).

On December 16, 2025, the US Securities and Exchange Commission’s (SEC) Division of Examinations released a risk alert, “Additional Observations Regarding Advisers’ Compliance with the Advisers Act Marketing Rule.”

A federal judge in the Central District of California recently denied a surf apparel brand’s request to halt sales of Lady Gaga’s Mayhem album merchandise.

For the past several years, the use of contract sales forces by pharmaceutical and device manufacturers and other suppliers has been under a heightened enforcement spotlight.

The California Department of Public Health (CDPH) denied two petitions to amend the hospital licensing regulations in Title 22 of the California Code of Regulations to allow advanced practice providers to be members of organized medical staffs in general acute care hospitals.

For the first time in 26 years, the US Food and Drug Administration (FDA) has proposed adding a new active ingredient to the list of permissible sunscreen actives in the United States.

Partner J. Michael Showalter was quoted on how non-governmental organizations focused on climate advocacy are expected to intensify litigation efforts this year against major oil and gas companies, regardless of multiple state court losses in 2025.

Life Sciences Industry Group Co-Leader Stephanie Trunk was quoted on Medicare’s updated drug price negotiation program under the Inflation Reduction Act being implemented in 2026.

The 2025 holiday retail shopping season is nearly a wrap. Consumers will be on the hunt for year-end discounts, and gift card purchases likely will surge over the coming days.

ArentFox Schiff is pleased to announce that Ucheora Onwuamaegbu has been appointed president of the Silicon Valley Arbitration & Mediation Center (SVAMC).

In this episode of Five Questions, Five Answers, Birgit Matthiesen and Jessica DiPietro explore the historical context and implications of the Nixon Shock and the Trade Expansion Act, focusing on Section 232 investigations and their impact on US trade policy.

On December 18, President Trump issued an executive order (EO) directing the Attorney General to complete rulemaking to reschedule “marijuana” from Schedule I to Schedule III under the Controlled Substances Act (CSA) and to expand federal research and policy development on medical marijuana and hemp derived cannabinoids.

The Centers for Medicare & Medicaid Services (CMS) Innovation Center has announced the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model, a 10‑year voluntary payment model that introduces outcome‑aligned payments (OAPs) to expand access to technology‑supported care for Medicare beneficiaries with common chronic conditions.

A magistrate judge of the US District Court for the District of Delaware issued a report and recommendation recommending the denial of the defendants’ Rule 12(b)(6) motion to dismiss SambaSafety’s Defend Trade Secrets Act (DTSA) claim arising from alleged misappropriation of driver compliance software and related data systems.